Nanovibronix Inc is a medical technology company focusing on the development and commercialization of proprietary therapeutic ultrasound devices for a range of healthcare applications. Their innovative products utilize non-invasive ultrasonic technology designed to enhance pain management, promote healing, and improve overall patient care. The company aims to address unmet clinical needs by providing effective and user-friendly solutions that can be integrated into various treatment protocols, enhancing the quality of life for patients while building partnerships with healthcare professionals and institutions. Read More
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
NanoVibronix, Inc. (the “Company”) (NASDAQ: NAOV) confirmed that a series of posts made earlier today with respect to a $26 million registered direct offering of common stock of the Company priced at $0.45 under Nasdaq rules was falsely issued by Flash Alert and FintelAlerts. The Company has not priced and is not consummating any registered direct offering. The Company is actively investigating this misinformation and will take necessary actions to protect its stockholders and its reputation.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division (“ENvue Medical”), that a major 420-bed acute care hospital located in the greater New Orleans area has selected the ENvue™ Navigation Platform (the “ENvue System”) to support adult feeding tube procedures. The hospital will transition from traditional blind insertions to real-time, electromagnetic-guided placement using the ENvue System.
NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, today announced the closing of its previously announced underwritten public offering of 400,000 shares of the Company’s Series G Convertible Preferred Stock (“Preferred Stock”), with a par value $0.001 per share and a stated value equal to $25, and Warrants to purchase up to 4,901,982 shares of common stock, par value $0.001 per share (the “Common Stock”) of the Company at an exercise price of $2.04 per share (the “Warrants”). The combined public offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00. The Warrants have a term of five years from the initial issuance date and are exercisable immediately upon issuance. The holders of the Preferred Stock are entitled to receive cumulative dividends at the rate per share of 9% per annum of the stated value per share until the fifth anniversary of the date of issuance of the Preferred Stock, which such dividends may be paid, at the Company’s option, in up to an aggregate of 2,205,883 shares of Common Stock.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, today announced the pricing of an underwritten public offering of approximately 400,000 shares of the Company’s Series G Convertible Preferred Stock (“Preferred Stock”), par value $0.001 per share and Warrants to purchase up to 4,901,961 shares of common stock, par value $0.001 per share (the “Common Stock”) of the Company at an exercise price of $2.04 per share (the “Warrants”). The combined public offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00. The closing of the public offering is expected to occur on or about May 19, 2025, subject to the satisfaction of customary closing conditions.
NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in therapeutic devices, today announced findings from a recent retrospective case series evaluating the clinical impact and patient experience of the UroShield™ system.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
